Calcifediol – more than the stepchild of CKD-MBD therapy?

Current Vascular Pharmacology

Volumn 12, Issue 2, 2014, Pages 286-293

  Brandenburg, Vincent M ^a   Krüger, Thilo ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Calcidiol; Calcifediol; Cholecalciferol; CKD MBD; Hyperparathyroidism; Parathyroid hormone; Vitamin D

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIFEDIOL; CALCITRIOL; CALCIUM; COLECALCIFEROL; CYTOCHROME P450 ISOENZYME; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; FIBROBLAST GROWTH FACTOR; VITAMIN D;

ARTICLE; BONE MINERALIZATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; END STAGE RENAL DISEASE; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL DISEASE; HUMAN; HYDROXYLATION; HYPERPARATHYROIDISM; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL OSTEODYSTROPHY; SURVIVAL; UREMIA; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION; BLOOD; COMPLICATION; LIVER; METABOLISM; RENAL INSUFFICIENCY, CHRONIC;

CALCIFEDIOL; FIBROBLAST GROWTH FACTORS; HUMANS; LIVER; PARATHYROID HORMONE; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84924502827     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990027     Document Type: Article

References (55)

1. [1] Slatopolsky E, Weerts C, Thielan J, et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984; 74(6):2136-43.
2. [2] Brandenburg VM, Vervloet MG, Marx N. The role of vitamin D in cardiovascular disease: From present evidence to future perspectives. Atherosclerosis 2012; 225(2):253-63.
3. [3] Brandenburg V, Ketteler M, Rodriguez M. Ten years of progress in our understanding of uremic vascular calcification and disease: a decade summarized in 20 steps. Kidney Int 2012; Suppl 1:116-21.
4. [4] Cozzolini M, Bover J, Vervloet M, Brandenburg V. A multidisciplinary review of the science of vitamin D receptor activation. Kidney Int 2011; 1(4):107-10.
5. [5] Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357(3):266-81.
6. [6] DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004; 80(6):1689-96.
7. [7] KDIGO clinical practice guideline for the diagnosis, evaluation, Prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;(113): 1-130.
8. [8] Ritter CS, Haughey BH, Armbrecht HJ, Brown AJ. Distribution and regulation of the 25-hydroxyvitamin D3 1alpha-hydroxylase in human parathyroid glands. J Steroid Biochem Mol Biol 2012; 130(1-2):73-80.
9. [9] Dusso AS, Finch J, Brown A, et al. Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 1991; 72(1):157-64.
10. [10] Urena-Torres P, Metzger M, Haymann JP, et al. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. Am J Kidney Dis 2011; 58(4):544-53.
11. [11] Clements MR, Davies M, Hayes ME, et al. The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol (Oxf) 1992; 37(1):17-27.
12. [12] Davies M, Heys SE, Selby PL, et al. Increased catabolism of 25-hydroxyvitamin D in patients with partial gastrectomy and elevated 1,25-dihydroxyvitamin D levels. Implications for metabolic bone disease. J Clin Endocrinol Metab 1997; 82(1):209-12.
13. [13] Barger-Lux MJ, Heaney RP, Dowell S, et al. Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporos Int 1998; 8(3):222-30.
14. [14] Lomonte C, Casucci F, Libutti P, et al. Vitamin D treatment in hemodialysis patients with low serum levels of parathyroid hormone: which is the best choice? J Nephrol 2010; 23(2):210-15.
15. [15] Clements MR, Johnson L, Fraser DR. A new mechanism for induced vitamin D deficiency in calcium deprivation. Nature 1987; 325(6099):62-5.
16. [16] Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72(8):1004-13.
17. [17] Drechsler C, Verduijn M, Pilz S, et al. Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2011; 26(3):1024-32
18. [18] Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16(4):1115-25.
19. [19] Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349(5):446-56.
20. [20] Drechsler C, Pilz S, Obermayer-Pietsch B, et al. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 2010; 31(18):2253-61.
21. [21] Michaud J, Dube P, Naud J, et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol 2005; 144(8):1067-77.
22. [22] Leblond F, Guevin C, Demers C, et al. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2001; 12(2):326-32.
23. [23] Michaud J, Naud J, Ouimet D, et al. Reduced hepatic synthesis of calcidiol in uremia. J Am Soc Nephrol 2010; 21(9):1488-97.
24. [24] Clements MR, Davies M, Fraser DR, et al. Metabolic inactivation of vitamin D is enhanced in primary hyperparathyroidism. Clin Sci (Lond) 1987; 73(6):659-64.
25. [25] Sitrin MD, Bengoa JM. Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in chronic cholestatic liver disease. Am J Clin Nutr 1987; 46(6):1011-5.
26. [26] Leichtmann GA, Bengoa JM, Bolt MJ, Sitrin MD. Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn's disease and intestinal resection. Am J Clin Nutr 1991; 54(3):548-52.
27. [27] Zabihiyeganeh M, Jahed A, Nojomi M. Treatment of hypovitaminosis D with pharmacologic doses of cholecalciferol, oral vs intramuscular; an open labeled RCT. Clin Endocrinol (Oxf) 2013; 78(2):210-6.
28. [28] LaClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005; 45(6):1026-33.
29. [29] Rosen CJ, Abrams SA, Aloia JF, et al. IOM committee members respond to Endocrine Society vitamin D guideline. J Clin Endocrinol Metab 2012; 97(4):1146-52.
30. [30] Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab 2012; 97(4):1153-8.
31. [31] Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168(15):1629-37.
32. [32] Farrell CJ, Martin S, McWhinney B, et al. State-of-the-art vitamin D assays: a comparison of automated immunoassays with liquid chromatography-tandem mass spectrometry methods. Clin Chem 2012; 58(3):531-42.
33. [33] Carter GD. 25-hydroxyvitamin D: a difficult analyte. Clin Chem 2012; 58(3):486-8.
34. [34] Sempos CT, Vesper HW, Phinney KW, et al. Vitamin D status as an international issue: national surveys and the problem of standardization. Scand J Clin Lab Invest Suppl 2012; 243:32-40.
35. [35] Kandula P, Dobre M, Schold JD, et al. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011; 6(1):50-62.
36. [36] Haddad JG, Jr., Rojanasathit S. Acute administration of 25-hydroxycholecalciferol in man. J Clin Endocrinol Metab 1976; 42(2):284-90.
37. [37] Gray RW, Weber HP, Dominguez JH, Lemann J,. The metabolism of vitamin D3 and 25-hydroxyvitamin D3 in normal and anephric humans. J Clin Endocrinol Metab 1974; 39(6):1045-56.
38. [38] Isidro ML, Ruano B. Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency. Endocrine 2009; 36(2):305-10.
39. [39] Bischoff-Ferrari HA, Dawson-Hughes B, Stocklin E, et al. Oral supplementation with 25(OH)D(3) versus vitamin D(3): effects on 25(OH)D levels, lower extremity function, blood pressure and markers of innate immunity. J Bone Miner Res 2011; 27(1):160-9.
40. [40] Rossini M, Viapiana O, Gatti D, et al. The long term correction of vitamin D deficiency: comparison between different treatments with vitamin D in clinical practice. Minerva Med 2005; 96(22):1-7.
41. [41] Cashman KD, Seamans KM, Lucey AJ, et al. Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults. Am J Clin Nutr 2012; 95(6):1350-6.
42. [42] Stamp TC, Haddad JG, Twigg CA. Comparison of oral 25-hydroxycholecalciferol, vitamin D, and ultraviolet light as determinants of circulating 25-hydroxyvitamin D. Lancet 1977; 1(8026):1341-3.
43. [43] Jean G, Terrat JC, Vanel T, et al. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant 2008; 23(11):3670-6.
44. [44] Kanter BJ, Crespo AJ, Beltran CS, et al. Vitamin D deficiency in a renal transplant population: safe repletion with moderate doses of calcidiol. Transplant Proc 2010; 42(8):2917-20.
45. [45] Russo S, Carlucci L, Cipriani C, et al. Metabolic changes following 500 mug monthly administration of calcidiol: a study in normal females. Calcif Tissue Int 2011; 89(3):252-7.
46. [46] Kronfol NO, Hersh WR, Barakat MM. Effects of 25(OH)-vitamin D3 in hypocalcemic patients on chronic hemodialysis. ASAIO Trans 1987; 33(3):289-92.
47. [47] Buccianti G, Bianchi ML, Valenti G, et al. Effects of calcifediol treatment on the progression of renal osteodystrophy during continuous ambulatory peritoneal dialysis. Nephron 1990; 56(4):353-6.
48. [48] Hesch RD, Gerlach W, Henning HV, et al. Studies on intestinal 47 Calcium absorption in healthy subjects and patients with chronic renal failure as well as on the significance of vitamin D 3 or 25-hydroxycholecalciferol therapy in renal osteopathy. Dtsch Med Wochenschr 1972; 97(45):1735-8.
49. [49] Wetmore JB, Liu S, Krebill R, et al. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2010; 5(1):110-6.
50. [50] Alvarez JA, Law J, Coakley KE, et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2012; 96(3):672-9.
51. [51] Teitelbaum SL, Bone JM, Stein PM, et al. Calcifediol in chronic renal insufficiency. Skeletal response. JAMA 1976; 235(2):164-7.
52. [52] Zucchelli P, Catizone L, Casanova S, et al. Therapeutic effects of 25-hydroxycholecalciferol and sodium etidronate on renal osteodystrophy. Miner Electrolyte Metab 1982; 7(2):86-96.
53. [53] Fournier A, Bordier P, Gueris J, et al. Comparison of 1 alphahydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization. Kidney Int 1979; 15(2):196-204.
54. [54] Recker R, Schoenfeld P, Letteri J, et al. The efficacy of calcifediol in renal osteodystrophy. Arch Intern Med 1978; 138: 857-63.
55. [55] Monier-Faugere MC, Malluche HH. Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transplant 1996; 11 Suppl 3:111-20.